Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Ms. Carrie L. Bourdow

Pres, Chief Executive Officer & Director

Mr. Barry  Shin

Senior Vice President & Chief Financial Officer

Dr. Mark A. Demitrack

Senior Vice President & Chief Medical Officer

Dr. Howard A. Rockman M.D.

Scientific Founder, Consultant and Member of Scientific Advisory Board

Mr. Joel  Solomon

Vice President, Gen. Counsel & Chief Compliance Officer

Mr. Michael  Catalano

Vice President of Marketing

Mr. Robert T. Yoder

Senior Vice President, Chief Bus. Officer & Head of Commercial Operations

Ms. Patricia M. Drake

Senior Vice President & Chief Commercial Officer

Biotecnología

Trevena, Inc.

Trevena, Inc. Estructura directiva

Información sobre la dirección